Access cutting-edge al amyloidosis treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.
Access al amyloidosis specialists in Stanford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related al amyloidosis treatment provided free
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Sponsor: Nexcella Inc.
Check if you qualify for this al amyloidosis clinical trial in Stanford, CA
If you're searching for al amyloidosis treatment options in Stanford, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced al amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.